Amedeo Smart

Free Medical Literature Service

 

Amedeo

Multiple Sclerosis
  Free Subscription

Articles published in
Neurology
    July 2026
  1. GUINEBRETIERE O, Yang F, Wei D, Calonge Q, et al
    Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022).
    Neurology. 2026;107:e218072.
    >> Share

    June 2026
  2. SHARMIN S, Roos I, Labauge PM, Filippi M, et al
    Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.
    Neurology. 2026;106:e218056.
    >> Share

  3. GOMBOLAY GY, Rubin JP
    Sometimes Kids Really Are Just Little Adults: Early Access to High-Efficacy Therapy Decreases Disability in Pediatric Multiple Sclerosis.
    Neurology. 2026;106:e218168.
    >> Share

  4. KIM W, Watt CL, Fung SG, Yoo S, et al
    Multiple Sclerosis and Outpatient Physician Care in the Last Years of Life: A Population-Based Study.
    Neurology. 2026;106:e218067.
    >> Share

    May 2026
  5. GAVOILLE A, Kerbrat A, Edan G, Le Page E, et al
    Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2026;106:e214943.
    >> Share

  6. PLUCHINO S, Mozafari S
    Early Human Intrathecal Mesenchymal Stem Cell Study in Progressive Multiple Sclerosis Faces Delivery Challenges.
    Neurology. 2026;106:e214955.
    >> Share

  7. KVISTAD CE, Krakenes T, Holmoy T, Eidem LE, et al
    Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS).
    Neurology. 2026;106:e214915.
    >> Share

  8. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214917.
    >> Share

    April 2026
  9. TOURNIER A, Gavoille A, Pique J, Levraut M, et al
    Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.
    Neurology. 2026;106:e214806.
    >> Share

  10. BOURDETTE D, Hartung DM
    Industry Payments to Physicians Alter the Care of Patients With Multiple Sclerosis: It's Time to Cut Financial Ties.
    Neurology. 2026;106:e214920.
    >> Share

  11. PATEL AN, Kesselheim AS, Rome BN
    Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.
    Neurology. 2026;106:e214834.
    >> Share

  12. DE JONG DJ, Schoonheim MM
    The Role of Wearable Devices to Identify Patients at High Risk of Disease Progression in Multiple Sclerosis.
    Neurology. 2026;106:e214742.
    >> Share

  13. FITZGERALD KC, Sanjayan M, Dewey BE, Guha Niyogi P, et al
    Association of Changes in Activity Patterns With Brain Atrophy and Disability Progression in People With Multiple Sclerosis.
    Neurology. 2026;106:e214678.
    >> Share

  14. KIM SH, Lee EJ, Lim YM, Kim H, et al
    Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea.
    Neurology. 2026;106:e214792.
    >> Share

  15. JACOBS BM, Schalk L, Tregaskis-Daniels E, Scalfari A, et al
    Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.
    Neurology. 2026;106:e214708.
    >> Share

  16. MARTINEZ SOSA S, Tisavipat N, Betting T, Guo Y, et al
    Pearls & Oy-sters: Using Susceptibility-Based Imaging in Highly Active Late-Onset Multiple Sclerosis.
    Neurology. 2026;106:e214794.
    >> Share

  17. LEODORI G, Maccarrone D, Mancuso M, De Bartolo MI, et al
    Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Patients With Multiple Sclerosis.
    Neurology. 2026;106:e214778.
    >> Share

  18. DESCHAMPS R, Papeix C, Demortiere S, Lardeux P, et al
    Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria.
    Neurology. 2026;106:e214753.
    >> Share

  19. ALFREDSSON L, Johansson E, Olsson T, Stridh P, et al
    Occupational Exposure to Industrial Dust and Rates of Multiple Sclerosis.
    Neurology. 2026;106:e214762.
    >> Share

    March 2026
  20. MILLER AE
    The 2024 McDonald Criteria for Diagnosis of Multiple Sclerosis: The Rubber Meets the Road.
    Neurology. 2026;106:e214688.
    >> Share

  21. BROWNLEE WJ, Maccarrone D, Nistri R, Yam C, et al
    Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis.
    Neurology. 2026;106:e214688.
    >> Share

  22. CHANDRA A, Acharya S, Chandra A
    Global & Community Health: Diagnosis and Management of Multiple Sclerosis in Nepal: Overcoming Barriers Through Local Adaptations.
    Neurology. 2026;106:e214743.
    >> Share

  23. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2026;106:e214694.
    >> Share

    February 2026
  24. LOCKHART A, Pisa M, Drakesmith H, DeLuca GC, et al
    Iron-Rim Lesions in the Optic Chiasm in Multiple Sclerosis: A Neuropathologic Case Series.
    Neurology. 2026;106:e214515.
    >> Share

  25. CAGOL A, Granziera C
    Turning Our Gaze to the Anterior Visual Pathway: Iron Rim Lesions Come Into View in Multiple Sclerosis.
    Neurology. 2026;106:e214590.
    >> Share

    January 2026
  26. BOS L, Wink AM, Cole JH, Strijbis EMM, et al
    Association of Brain Age With Physical Disability and Cognitive Impairment in People With Multiple Sclerosis of the Same Age.
    Neurology. 2026;106:e214527.
    >> Share

  27. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214473.
    >> Share

  28. MOCCIA M, Silbermann E
    Can Once-Yearly Rituximab Dosing Be "Enough" for Most People With Relapsing Multiple Sclerosis?
    Neurology. 2026;106:e214586.
    >> Share

  29. SPAIN RI, Paz Soldan MM, Freedman MS, Repovic P, et al
    Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.
    Neurology. 2026;106:e214454.
    >> Share

  30. BRIGGS FBS, Amezcua L
    Alpha Lipoic Acid in Multiple Sclerosis: It's All in the Details.
    Neurology. 2026;106:e214578.
    >> Share

    December 2025
  31. DAMULINA A, Opriessnig P, Pirpamer L, Demjaha R, et al
    Association of CSF Kappa-Free Light Chains With Cortical and Periventricular Brain Damage in Multiple Sclerosis.
    Neurology. 2025;105:e214433.
    >> Share

  32. TRENTADUE T, Martinez Sosa S, Itoh CY, Modi T, et al
    Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.
    Neurology. 2025;105:e214429.
    >> Share

  33. DE MEO E, Addazio I, Portaccio E, Bonacchi R, et al
    Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.
    Neurology. 2025;105:e214408.
    >> Share

    November 2025
  34. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
    Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
    Neurology. 2025;105:e214158.
    >> Share

  35. KOZIK V, Dreiling M, Muller D, Tiedge O, et al
    Multiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment: A Cross-Sectional Study.
    Neurology. 2025;105:e214217.
    >> Share

  36. HOGUE O, Zelinsky M, Sonneborn C, Anantasagar T, et al
    Association of Statistical Methodology and Design in Preclinical Animal Studies With Successful Translation Into Clinical Phase 2 Trials.
    Neurology. 2025;105:e214250.
    >> Share

  37. PIERRET C, Leray E
    Author Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210260.
    >> Share

  38. GANESH A, Galetta SL
    Editors' Note: Understanding Cancer Risk Among Patients With Multiple Sclerosis.
    Neurology. 2025;105:e214342.
    >> Share

  39. SONG Y, Wang L, Xuan Z
    Reader Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210222.
    >> Share

  40. FENG Q
    Reader Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210223.
    >> Share

    October 2025
  41. OLIVIERI E, Muller J, Toosy AT
    Predicting Disability Using PIRA in Multiple Sclerosis: Is It as Straightforward as It Appears?
    Neurology. 2025;105:e214206.
    >> Share

  42. PORTACCIO E, Betti M, De Meo E, Pasto L, et al
    Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2025;105:e213977.
    >> Share

  43. O'NEILL KA, Charvet L, Waltz M, George A, et al
    Cognitive Function in People With Pediatric Multiple Sclerosis Over 2 Years.
    Neurology. 2025;105:e214142.
    >> Share

  44. PORTACCIO E, Amato MP
    Moving Closer to the Prevention of Cognitive Disability in People With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;105:e214244.
    >> Share

  45. SAHI N, Ciccarelli O, Houlden H, Chard DT, et al
    Unlocking Multiple Sclerosis Genetics: From Susceptibility to Severity.
    Neurology. 2025;105:e214141.
    >> Share

  46. BSTEH G, Hegen H, Krajnc N, Fottinger F, et al
    Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple Sclerosis.
    Neurology. 2025;105:e214069.
    >> Share

    September 2025
  47. CORTESE R, Sforazzini F, Gentile G, de Mauro A, et al
    Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated Disease.
    Neurology. 2025;105:e214075.
    >> Share

  48. CHARD DT
    Diagnosing Multiple Sclerosis: An Imperfect but Evolving Process.
    Neurology. 2025;105:e214057.
    >> Share

  49. RENNER B, Verter ED, Absinta M, Daboul L, et al
    Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic.
    Neurology. 2025;105:e213912.
    >> Share

    August 2025
  50. GAVOILLE A, Leray E, Marignier R, Rollot F, et al
    Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.
    Neurology. 2025;105:e213907.
    >> Share

  51. BSTEH G, Hegen H
    Bridging the Sex Gap: Confronting Therapeutic Inertia in Women With Multiple Sclerosis.
    Neurology. 2025;105:e214073.
    >> Share

  52. AL-ARAJI S, Moccia M, Jha A, Zhang L, et al
    Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2025;105:e213967.
    >> Share

  53. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;105:e213909.
    >> Share

  54. CORTESE M, Peng X, Edan G, Freedman MS, et al
    Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
    Neurology. 2025;105:e213905.
    >> Share

  55. BOURDETTE D, Wooliscroft L
    Late-Onset Multiple Sclerosis: Is Disease-Modifying Therapy Indicated?
    Neurology. 2025;105:e213971.
    >> Share

  56. ROBIN C, Rollot F, Lefort M, Casey R, et al
    Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.
    Neurology. 2025;105:e213744.
    >> Share

    July 2025
  57. JIA A, Price TR, Rosner J, Broderick C, et al
    Journal Club: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e213663.
    >> Share

    June 2025
  58. GOYNE C, Fair AE, Yilmaz D, Race J, et al
    Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;104:e213673.
    >> Share

  59. YEH EA
    Accelerated Aging in Children With Multiple Sclerosis: Can We Stop the Clock?
    Neurology. 2025;104:e213840.
    >> Share

  60. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
    Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
    Neurology. 2025;104:e213650.
    >> Share

    May 2025
  61. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EMM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2025;104:e213618.
    >> Share

  62. FOX RJ, Rudick RA
    A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability Worsening.
    Neurology. 2025;104:e213672.
    >> Share

  63. LANGER-GOULD A, Li BH, Smith JB, Kanter MH, et al
    Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level.
    Neurology. 2025;104:e213607.
    >> Share

  64. KAPPOS L, Yiu S, Dahlke F, Coetzee T, et al
    Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.
    Neurology. 2025;104:e213558.
    >> Share

  65. CHAGGAR G, Waldner D, Scozzafava J, Harrison R, et al
    Teaching NeuroImage: Severe Enterovirus Encephalitis as a Complication of Ocrelizumab Treatment for Multiple Sclerosis.
    Neurology. 2025;104:e213585.
    >> Share

  66. MARRIE RA, Sharma M, Cutter GR, Fox RJ, et al
    Perspectives of People With Multiple Sclerosis Regarding Data Linkage and Sharing.
    Neurology. 2025;104:e213587.
    >> Share

  67. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;104:e213574.
    >> Share

  68. GUINEBRETIERE O, Pierret C, Calonge Q, Januel E, et al
    Updated Multiple Sclerosis Incidence in France, 2011-2021.
    Neurology. 2025;104:e213586.
    >> Share

    April 2025
  69. GANESH A, Galetta SL
    Editors' Note: Domestic Violence and Abuse in People Living With Multiple Sclerosis.
    Neurology. 2025;104:e213407.
    >> Share

  70. BROWNLEE WJ, Foster MA, Pontillo G, Davagnanam I, et al
    Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis.
    Neurology. 2025;104:e210274.
    >> Share

  71. VIDAL-JORDANA A, Ontaneda D
    To Kill Time: A Bold Step Toward Simplifying Multiple Sclerosis Diagnosis.
    Neurology. 2025;104:e213416.
    >> Share

  72. MAHAJAN KR, Herman D, Zheng Y, Androjna C, et al
    Neurodegeneration and Demyelination in the Multiple Sclerosis Spinal Cord: Clinical, Pathological, and 7T MRI Perspectives.
    Neurology. 2025;104:e210259.
    >> Share

    March 2025
  73. GOMEZ-FIGUEROA E, Moreno-Bernardino CJ, De Alba-Sanchez AM, Guerrero-Udave N, et al
    The Burden of Multiple Sclerosis in Mexico.
    Neurology. 2025;104:e213343.
    >> Share

    February 2025
  74. TRANFA M, Petracca M, Moccia M, Scaravilli A, et al
    Conventional MRI-Based Structural Disconnection and Morphometric Similarity Networks and Their Clinical Correlates in Multiple Sclerosis.
    Neurology. 2025;104:e213349.
    >> Share

  75. MARRIE RA, Bolton J, Ling YV, Bernstein C, et al
    Peripartum Mental Illness in Mothers With Multiple Sclerosis and Other Chronic Diseases in Ontario, Canada.
    Neurology. 2025;104:e210170.
    >> Share

  76. ROSS LA
    Peripartum Mental Illness in Mothers With Multiple Sclerosis Merits Neurologists' Attention.
    Neurology. 2025;104:e213366.
    >> Share

  77. DERSCH RS, Fingerle V, Berns J, Rauer S, et al
    Pearls & Oy-sters: Recurrent Lyme Neuroborreliosis With Seroreversion in a Patient With Multiple Sclerosis on a B-Cell Depleting Therapy.
    Neurology. 2025;104:e213330.
    >> Share

  78. CERQUEIRA JJ, Berthele A, Cree BAC, Filippi M, et al
    Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
    Neurology. 2025;104:e210142.
    >> Share

  79. ROCCA MA, Preziosa P, Filippi M
    Age Matters in Multiple Sclerosis: Novel Insights Into Disease Progression From Clinical Onset.
    Neurology. 2025;104:e213396.
    >> Share

  80. COBO-CALVO A, Carbonell-Mirabent P, Tur C, Otero-Romero S, et al
    Age-Related Disability Outcomes After a First Demyelinating Event.
    Neurology. 2025;104:e210305.
    >> Share

  81. BRENTON JN
    Menarche and Relapses in Multiple Sclerosis: Associations Between a Physiologic Developmental Milestone and Disease Activity.
    Neurology. 2025;104:e213321.
    >> Share

  82. KRYSKO KM, Waltz M, Chitnis T, Weinstock-Guttman B, et al
    Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis.
    Neurology. 2025;104:e210213.
    >> Share

  83. BALCOM EF, Mccombe JA, Kate MP, Vu K, et al
    Inequities in the Use of Disease-Modifying Therapy Among Adults Living With Multiple Sclerosis in Urban and Rural Areas in Alberta, Canada.
    Neurology. 2025;104:e210251.
    >> Share

  84. CARVAJAL R, Guananga-Alvarez D, Tur C, Esperalba J, et al
    Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.
    Neurology. 2025;104:e210281.
    >> Share

  85. AMEZCUA L, Cardenas-Iniguez C, Orlando C, Martinez A, et al
    Person-Centered Social Determinants and Neighborhood-Level Deprivation Associated With Disability in Hispanic People With Multiple Sclerosis.
    Neurology. 2025;104:e213332.
    >> Share

    January 2025
  86. TSAI CC, Chen J, Pikula A, Johnson EL, et al
    Opinion & Special Articles: Beyond Pronouns-Educating Trainees on the Impact of Language on Gender Inclusivity in Neurologic Practice.
    Neurology. 2025;104:e210289.
    >> Share

  87. CAGOL A, Montobbio N
    Reassuring Insights Into the Effect of COVID-19 on Symptoms and Disability in People With Multiple Sclerosis: Weathering the Storm.
    Neurology. 2025;104:e210272.
    >> Share

  88. SILVERMAN HE, Bostrom A, Nylander AN, Akula A, et al
    Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.
    Neurology. 2025;104:e210228.
    >> Share

  89. SALTER A, Lancia S, Cutter GR, Fox RJ, et al
    Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis.
    Neurology. 2025;104:e210149.
    >> Share

  90. CRUCIANI A, Toosy AT
    Progression Independent of Relapse Activity in Multiple Sclerosis: More, or Less, Than Meets the Eye?
    Neurology. 2025;104:e210296.
    >> Share

  91. STRIJBIS EMM, Mostert J, Comtois J, Salter A, et al
    Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2025;104:e210153.
    >> Share

  92. MONGAY-OCHOA N, Pareto D, Alberich M, Carbonell-Mirabent P, et al
    Association of the Cervical Canal Area With Disability and Progression in People With Multiple Sclerosis.
    Neurology. 2025;104:e210136.
    >> Share

    December 2024
  93. RIMKUS CM, Nucci MP, Avolio IB, Apostolos-Pereira SL, et al
    Atrophy Patterns in Patients With Multiple Sclerosis With Cognitive Impairment, Fatigue, and Mood Disorders.
    Neurology. 2024;103:e210080.
    >> Share

  94. ROSS R, O'Neill KA, Betensky RA, Billiet T, et al
    Association of Social Determinants of Health With Brain MRI Outcomes in Individuals With Pediatric Onset Multiple Sclerosis.
    Neurology. 2024;103:e210140.
    >> Share

  95. HARTUNG HP, Benedict RHB, Berger T, Bermel RA, et al
    Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
    Neurology. 2024;103:e210049.
    >> Share

  96. QUINN CM, Rajarajan P, Gill AJ, Kopinsky H, et al
    Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.
    Neurology. 2024;103:e210003.
    >> Share

  97. WILSON E, Meeks HD, Barney BJ, Waltz M, et al
    Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States.
    Neurology. 2024;103:e209991.
    >> Share

    November 2024
  98. REEVES JA, Bartnik A, Jakimovski D, Mohebbi M, et al
    Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.
    Neurology. 2024;103:e210004.
    >> Share

  99. WATANABE M, Isobe N, Niino M, Nakashima I, et al
    Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.
    Neurology. 2024;103:e209992.
    >> Share

  100. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
    Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
    Neurology. 2024;103:e210029.
    >> Share

  101. MICHAELSON NM, Klawiter EC, Singhal T
    Journal Club: PET Imaging in Multiple Sclerosis and Its Prognostic Implications.
    Neurology. 2024;103:e210047.
    >> Share

  102. PONTILLO G, Prados F, Colman J, Kanber B, et al
    Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.
    Neurology. 2024;103:e209976.
    >> Share

  103. BROEDERS TAA, van Dam M, Pontillo G, Rauh V, et al
    Energy Associated With Dynamic Network Changes in Patients With Multiple Sclerosis and Cognitive Impairment.
    Neurology. 2024;103:e209952.
    >> Share

  104. PIERRET C, Mulliez A, Le Bihan-Benjamin C, Moisset X, et al
    Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2024;103:e209885.
    >> Share

    October 2024
  105. SIEGLER JE 3RD, Galetta S
    Editors' Note: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209893.
    >> Share

  106. GROBOIS L, You M, Etienne M
    Reader Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209508.
    >> Share

  107. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Author Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209515.
    >> Share

  108. HAY M, Rollot F, Casey R, Kerbrat A, et al
    Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
    Neurology. 2024;103:e209886.
    >> Share

  109. YOKOTE H, Mori K, Nakamichi K, Matsuda T, et al
    Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML.
    Neurology. 2024;103:e209874.
    >> Share


  110. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;103:e209461.
    >> Share


  111. Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results From Structured Interviews (P1-6.015).
    Neurology. 2024;103:e209905.
    >> Share

  112. LOONSTRA FC, Alvarez Sirvent D, Tesi N, Holstege H, et al
    Association of Polygenic Risk Score With Lifetime Risk of Developing Multiple Sclerosis in a Population-Based Birth-Year Cohort.
    Neurology. 2024;103:e209663.
    >> Share

    September 2024
  113. ROVIRA A, Pareto D
    chi-Separation as a Novel MRI Biomarker for Assessing Disease Progression in Multiple Sclerosis: Divide and Conquer.
    Neurology. 2024;103:e209735.
    >> Share

  114. MULLER J, Lu PJ, Cagol A, Ruberte E, et al
    Quantifying Remyelination Using chi-Separation in White Matter and Cortical Multiple Sclerosis Lesions.
    Neurology. 2024;103:e209604.
    >> Share

  115. BOURDETTE D
    Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy Treatment.
    Neurology. 2024;103:e209835.
    >> Share

  116. BSTEH G, Aicher ML, Walde JF, Krajnc N, et al
    Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
    Neurology. 2024;103:e209752.
    >> Share

  117. BANKS SA, Brinjikji W, Giannini C, Syc-Mazurek SB, et al
    Intra-arterial Melphalan as Targeted Therapy for Tumefactive Multiple Sclerosis Lesions.
    Neurology. 2024;103:e209739.
    >> Share

  118. ABBOUD H, Farez MF
    The Risk of Multiple Sclerosis Relapse After Vaccination: Can a Population-Based Study of Mass Vaccination End the Longstanding Debate?
    Neurology. 2024;103:e209761.
    >> Share

  119. MOISSET X, Leray E, Chenaf C, Taithe F, et al
    Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.
    Neurology. 2024;103:e209662.
    >> Share

    August 2024
  120. KARALIUS M, Mohan S, Paredes D, Rasool N, et al
    Pearls & Oy-sters: Optic Neuritis as First Demyelinating Event During Pregnancy in 2 Young Hispanic Women: MS vs MOGAD.
    Neurology. 2024;103:e209706.
    >> Share

  121. SASTRE-GARRIGA J, Vidal-Jordana A, Toosy AT, Enzinger C, et al
    Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives.
    Neurology. 2024;103:e209677.
    >> Share

  122. WILLIAMS MJ, Amezcua L, Cohan SL, Cohen JA, et al
    Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
    Neurology. 2024;103:e209610.
    >> Share

    July 2024
  123. PFEUFFER S, Wolff S, Aslan D, Rolfes L, et al
    Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
    Neurology. 2024;103:e209574.
    >> Share

  124. CICCARELLI O, Barkhof F, Calabrese M, De Stefano N, et al
    Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
    Neurology. 2024;103:e209444.
    >> Share

  125. MADSEN MA, Povazan M, Wiggermann V, Lundell H, et al
    Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis.
    Neurology. 2024;103:e209543.
    >> Share

    June 2024
  126. PALLADINO R, Monasta L
    Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
    Neurology. 2024;102:e209521.
    >> Share

  127. ZHANG C, Liu W, Wang L, Wang F, et al
    Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
    Neurology. 2024;102:e209351.
    >> Share

    May 2024
  128. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
    Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Neurology. 2024;102:e209303.
    >> Share

  129. SILBERMANN E, Spain RI
    Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
    Neurology. 2024;102:e209456.
    >> Share

  130. FOX RJ, Cree BAC, de Seze J, Gold R, et al
    Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209357.
    >> Share

  131. MICHAELSON NM
    Right Brain: The Unraveling.
    Neurology. 2024;102:e209492.
    >> Share

  132. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
    Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
    Neurology. 2024;102:e209350.
    >> Share

    April 2024

  133. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
    Neurology. 2024;102:e209214.
    >> Share

  134. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
    MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
    Neurology. 2024;102:e209199.
    >> Share

  135. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
    Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Neurology. 2024;102:e208114.
    >> Share

  136. YU Y, Kushlaf H
    Multiple Sclerosis in a Patient with Friedreich's Ataxia (P4-6.016).
    Neurology. 2024;102.
    >> Share

  137. WATANABE F, Fedorko J, Imitola J
    Dimethyl Fumarate Enhances Neural Stem Cell (NSC) Self-renewal and Neuroprotection in a Human Cellular Model of Multiple Sclerosis Inflammation-induced Neurodegeneration (P8-6.014).
    Neurology. 2024;102.
    >> Share

  138. LOBAINA M, Valaparla VL, Shanina E
    Vogt-Koyanagi-Harada Disease an Autoimmune Comorbidity of Multiple Sclerosis, Not Just a Mimicker (P3-14.014).
    Neurology. 2024;102.
    >> Share

  139. KARAYI G, Quinones-Herrero N, Martin J, Chaudhry S, et al
    A Retrospective Analysis of Disease Modifying Drug Discontinuation in Patients with Multiple Sclerosis (S31.010).
    Neurology. 2024;102.
    >> Share

  140. ROSE M, Hsu S, Balan A, Anderson A, et al
    Risk Factors for Peripartum Mood Disorders in Women with MS: A Prospective Study (P4-6.014).
    Neurology. 2024;102.
    >> Share

  141. WOODSON S, Gettings E, Guo CY, Klineova S, et al
    Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005).
    Neurology. 2024;102.
    >> Share

  142. MIKAMI T, Levy M
    Association of HLA-DRB1*15:01 Status with Transcriptomic Pattern of B cells in CSF in Multiple Sclerosis (P7-6.011).
    Neurology. 2024;102.
    >> Share

    March 2024
  143. MARRIE RA, Salter A
    Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
    Neurology. 2024;102:e208099.
    >> Share

  144. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
    Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e208032.
    >> Share


  145. Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209252.
    >> Share

  146. BOURDETTE D, Wooliscroft L
    The Challenges of Treating Late-Onset Multiple Sclerosis.
    Neurology. 2024;102:e209146.
    >> Share

  147. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
    Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;102:e208051.
    >> Share

  148. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;102:e209135.
    >> Share

  149. CHARD DT
    Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Neurology. 2024;102:e209246.
    >> Share

  150. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
    Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Neurology. 2024;102:e208058.
    >> Share

  151. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
    Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
    Neurology. 2024;102:e209147.
    >> Share

    February 2024
  152. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
    Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
    Neurology. 2024;102:e208100.
    >> Share

  153. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e207966.
    >> Share

  154. NG HS, Zhu F, Zhao Y, Yao S, et al
    Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
    Neurology. 2024;102:e208006.
    >> Share

  155. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
    Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
    Neurology. 2024;102:e208059.
    >> Share

    January 2024
  156. GIBSON S, Mcgraw C
    Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
    Neurology. 2024;102:e208027.
    >> Share

  157. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
    Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
    Neurology. 2024;102:e207916.
    >> Share

  158. LANGER-GOULD A, Sotirchos ES, Bourdette D
    Rituximab for Multiple Sclerosis.
    Neurology. 2024;102:e208063.
    >> Share

  159. GALETTA S, Brownlee W
    Assignment Completed.
    Neurology. 2024;102:e207913.
    >> Share

  160. TUR C, Rocca MA
    Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2024;102:e207936.
    >> Share

  161. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
    Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
    Neurology. 2024;102:e200805.
    >> Share

  162. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
    Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
    Neurology. 2024;102:e207768.
    >> Share

    December 2023
  163. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
    Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
    Neurology. 2023;101:e2483-e2496.
    >> Share

  164. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
    Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
    Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
    >> Share

    October 2023
  165. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
    Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
    >> Share

    September 2023
  166. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
    Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
    Neurology. 2023;101:e1280-e1292.
    >> Share

  167. PALLADINO R, Strijbis EM
    How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
    >> Share

  168. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
    Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
    >> Share

  169. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
    Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
    >> Share

  170. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
    Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
    >> Share

  171. BUYUKKURT A, Harroud A
    The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
    >> Share

    August 2023
  172. BSTEH G, Hegen H, Altmann P, Auer M, et al
    Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis.
    Neurology. 2023;101:e784-e793.
    >> Share

  173. GRAVES JS
    Cell Specific Aging in Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207679.
    >> Share

  174. MALTBY V, Xavier A, Ewing E, Campagna MP, et al
    Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207489.
    >> Share

    July 2023
  175. FADDA G, Cardenas de la Parra A, O'Mahony J, Waters P, et al
    Deviation From Normative Whole Brain and Deep Gray Matter Growth in Children With MOGAD, MS, and Monophasic Seronegative Demyelination.
    Neurology. 2023;101:e425-e437.
    >> Share

  176. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
    Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
    >> Share

  177. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
    Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
    >> Share

  178. LONGBRAKE E, Kalincik T
    Early Treatment for Multiple Sclerosis: Time Is Brain.
    Neurology. 2023 Jul 19:10.1212/WNL.0000000000207754.
    >> Share

  179. EHRHARDT H, Lambe J, Moussa H, Vasileiou ES, et al
    Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post-Hoc Analyses of the SPRINT-MS Trial.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207551.
    >> Share

  180. BENNETT JL
    Sprinting to the Finish: Optical Coherence Tomography, Retinal Atrophy, and Neurodegeneration in Progressive Multiple Sclerosis.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207607.
    >> Share

  181. JAIN A, Arena VP, Steigerwald C, Borja MJ, et al
    Pearls and Oy-sters: CSF1R-Related Leukoencephalopathy With Spinal Cord Lesions Mimicking Multiple Sclerosis.
    Neurology. 2023 Jul 5:10.1212/WNL.0000000000207502.
    >> Share

  182. TOOSY AT, Vidal-Jordana A
    Is the Optic Nerve Overdue as a Criterion to Support the Diagnosis of Multiple Sclerosis?
    Neurology. 2023 Jul 3:10.1212/WNL.0000000000207625.
    >> Share

    June 2023
  183. KOCH-HENRIKSEN N
    Worldwide Disparity in the Effectiveness of the Diagnostic Process in Multiple Sclerosis.
    Neurology. 2023 Jun 30:10.1212/WNL.0000000000207530.
    >> Share

  184. SOLOMON AJ, Marrie RA, Viswanathan S, Correale J, et al
    Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition.
    Neurology. 2023 Jun 15:10.1212/WNL.0000000000207481.
    >> Share

  185. ROTSTEIN D, Schneider R
    A Birth Year Cohort and What It Can Reveal About Lipid Mediators as Putative Biomarkers of Progression in Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207605.
    >> Share

  186. BROOS JY, Loonstra FC, de Ruiter LRJ, Gouda MMTEE, et al
    Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207459.
    >> Share

  187. KOWALEC K, Fitzgerald KC, Salter A, Dolovich C, et al
    Polygenicity of Comorbid Depression in Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207457.
    >> Share

    April 2023
  188. LUSK JB, Hoffman MN, Clark AG, Bae J, et al
    Association Between Neighborhood Socioeconomic Status and 30-Day Mortality and Readmission for Patients With Common Neurologic Conditions.
    Neurology. 2023;100:e1776-e1786.
    >> Share

  189. LEAVITT VM
    The Mismeasure of Change: Better Cognitive Measurement Instruments are Urgently Needed for Multiple Sclerosis Research.
    Neurology. 2023 Apr 18:10.1212/WNL.0000000000207431.
    >> Share

  190. CASTROGIOVANNI N, Mostert J, Repovic P, Bowen JD, et al
    Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
    Neurology. 2023 Apr 18:10.1212/WNL.0000000000207301.
    >> Share

    March 2023
  191. CARTA S, Cobo Calvo A, Armangue T, Saiz A, et al
    Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.
    Neurology. 2023;100:e1095-e1108.
    >> Share

    September 2022
  192. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
    Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016